{"id":60561,"date":"2024-10-15T12:05:27","date_gmt":"2024-10-15T12:05:27","guid":{"rendered":"https:\/\/english.saigonbiz.com.vn\/2024\/10\/15\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/"},"modified":"2024-10-15T12:05:27","modified_gmt":"2024-10-15T12:05:27","slug":"galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting","status":"publish","type":"post","link":"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/","title":{"rendered":"Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting"},"content":{"rendered":"<div>\n<p align=\"left\">NORCROSS, Ga., Oct.  15, 2024  (GLOBE NEWSWIRE) &#8212; <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uMH9S-08eWcHWY9EqdJUlMVubXfLeYqf2Gftmr0-aIUyUgxRr2cuQqYkNWzB7fvtUkA97XCI9I5cKnVtWwCnM8f4zXzDMHB4Hp0CfJGC6MH7zGIwyBDTpervDwhNj3bb\" rel=\"nofollow noopener\" target=\"_blank\" title=\"Galectin Therapeutics, Inc.\">Galectin Therapeutics, Inc.<\/a> (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b\/3 adaptive, NAVIGATE trial in patients with MASH cirrhosis and portal hypertension have been accepted for poster presentation at the American Association for the Study of Liver Diseases (AASLD)\u2019s annual meeting, 2024 Liver Meeting, being held November 15-19, 2024 in San Diego, California.<\/p>\n<p>All three posters highlighting clinical data will be presented at the \u201cPortal Hypertension and Other Complications of Cirrhosis\u201d session taking place 8:00 am \u2013 5:00 pm on November 18, 2024:<\/p>\n<p><strong>Title:<\/strong> Evaluation of esophageal and gastric varices in cirrhotic patients with portal hypertension: a central evaluation system for clinical research.<br \/><strong>Abstract Number:<\/strong> 4118<br \/><strong>Presenter:<\/strong> Naim Alkhouri, M.D., Arizona Liver Health, Chandler, AZ<\/p>\n<p><strong>Title:<\/strong> Baseline patients\u2019 characteristics from NAVIGATE, a seamless adaptive Phase 2b\/3 trial of Belapectin in MASH cirrhosis and portal hypertension.<br \/><strong>Abstract Number:<\/strong> 4063<br \/><strong>Presenter:<\/strong> Khurram Jamil, M.D., Chief Medical Officer, Galectin Therapeutics<\/p>\n<p><strong>Title:<\/strong> In patients with compensated MASH cirrhosis with platelet count &lt; 150,000\/\u00b5L and radiologic findings of portal hypertension, a third are identified with esophageal varices on screening Esophago-Gastroduodenoscopy.<br \/><strong>Abstract Number:<\/strong> 4125<br \/><strong>Presenter: <\/strong>Laura Ladron deGuevar, M.D., CIAID &#8211; Centro de Investigacion y Atencion Integral Durango, S.C.<\/p>\n<p>Abstracts are available for viewing by attendees on the AASLD website and will also be featured in the October supplement to the AASLD journal, <em>Hepatology<\/em>.<\/p>\n<p><strong>About Galectin Therapeutics<\/strong><br \/>Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin\u2019s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=5bz6chofoYy_-iCwuRY-ha1J2Q-oqDwGJ8sCR1Fwa2fAbLBmzSRzk1K-SEW6ZMe-fa-QEd68fUVwXSzFVAf4LsB7sx5Z0x1qCBN26ZkSkb8P3OIDMEKH54UlOwr-6y4vI-wUYb_5ADoc3CJnRoCLXjBphwDsoLtm1FAh4Aa6YdL0WKYOMwIxaiwMtChBnnk1wYjNDyWWDUtPh4zCpbtpSqAgG7v3b6ZY1IUCVif265fWN-oEiQeJrE2vLgtT0ozuWcdSx_C8xTHZFMhYBZSagZlCFuKCiHs3fe5h0sV4c8o=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"\"><strong><u>www.galectintherapeutics.com<\/u><\/strong><\/a>.<\/p>\n<p align=\"justify\"><strong>Company Contact:<\/strong><\/p>\n<p align=\"justify\">Jack Callicutt, Chief Financial Officer<br \/>(678) 620-3186<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=XaXyZwGXuns57x3i5x-FzsKY4uCyxQsPMvk4_zev1T_Q1liY6i4qbquoLSXvlolS1cG3NpF5B40sGIB-pbpgw8_DI7PpB4-Y0cr3aKo0CWeiCqcL4lm7BTaNYINopcRp\" rel=\"nofollow noopener\" target=\"_blank\" title=\"ir@galectintherapeutics.com\">ir@galectintherapeutics.com<\/a><\/p>\n<p align=\"justify\"><strong>Investors Relations Contacts:<\/strong><br \/>Kevin Gardner<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=OWsUVtGxqRYgpurrgUKqk0ILbFolF_e75mJnh1pFdJ43Pf4XMfUJqHuOpcL4pPuuJSpvSJy-vB5Wg3CidTZ_ZZfy0gINb_Dm3Fcs34AJEiK2IXAZQZDRmBPbH6KpmMecCSOQ9nGYtHi_BXgBEVPtUUmJ7fHJ8DtixnOlzZSaU_t2I9zg7SOWKo3IqRlSU_O76dGQy0t32uKAG-0T319pGccfMj5f3bP0okcjNyx6GqaaA_qAnch0AE-wJtA6G_L_mEbfuO_TOzrxRKcTg1NHKpQ__TFvXKgt59oz7n7-7Ms=\" rel=\"nofollow noopener\" target=\"_blank\" title=\"kgardner@lifesciadvisors.com\">kgardner@lifesciadvisors.com<\/a><\/p>\n<p align=\"justify\">Chris Calabrese<br \/><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=CmJo-NCXTEz-p5BjGV6fP9lPsWBdVcooQcFSfxif0rlu6ofHlQt2Qs6QemlA_T2KooOqMTWxJBDcMT1dIgQdlEKdxj532ks3iA6qINRIu-xAHaZ6qvLg6cTeFkhfpbmSvHE9CZaa_uqQvVgsirlQpeGXnigx33hLanUe69fq8qt6p74T-es0B1oIDSgpaIv5QiAQNj805pEuIZMVrpXENuhUmpC1Fg00wNcth_kp3H7NdwZkClxfQmkKF_7jxyT_iHKEPj70tfF1Ek98Lz3wURwB3B5RX9TZlds-X5zc4xU9f6sItaUUs2aSsqvHGdMJ\" rel=\"nofollow noopener\" target=\"_blank\" title=\"ccalabrese@lifesciadvisors.com\">ccalabrese@lifesciadvisors.com<\/a><\/p>\n<p>Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics\u2019 galectin-3 inhibitor belapectin.<\/p>\n<p><img decoding=\"async\" src=\"https:\/\/ml.globenewswire.com\/media\/NDFkZDU4NzgtN2Y2ZS00YTdjLWEzNWQtMjc5ZDkzNTIyYWM3LTEwMjEyMjY=\/tiny\/Galectin-Therapeutics-Inc-.png\" referrerpolicy=\"no-referrer-when-downgrade\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) &#8212; Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that three abstracts from ongoing Phase 2b\/3 adaptive, NAVIGATE trial in patients with MASH cirrhosis and portal hypertension have been accepted for poster presentation at the American Association for the Study [&#8230;]\n","protected":false},"author":1,"featured_media":60562,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[],"class_list":["post-60561","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-pr-newswire"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v21.6 (Yoast SEO v21.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - Biz and Live in Saigon<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting\" \/>\n<meta property=\"og:description\" content=\"NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) &#8212; Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target ga\" \/>\n<meta property=\"og:url\" content=\"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/\" \/>\n<meta property=\"og:site_name\" content=\"Biz and Live in Saigon\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/SaigonbizGroup\" \/>\n<meta property=\"article:published_time\" content=\"2024-10-15T12:05:27+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Galectin-Therapeutics-Inc-.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1\" \/>\n\t<meta property=\"og:image:height\" content=\"1\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"admin\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"admin\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/\"},\"author\":{\"name\":\"admin\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\"},\"headline\":\"Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting\",\"datePublished\":\"2024-10-15T12:05:27+00:00\",\"dateModified\":\"2024-10-15T12:05:27+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/\"},\"wordCount\":469,\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"articleSection\":[\"Pr Newswire\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/\",\"name\":\"Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - Biz and Live in Saigon\",\"isPartOf\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\"},\"datePublished\":\"2024-10-15T12:05:27+00:00\",\"dateModified\":\"2024-10-15T12:05:27+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/english.saigonbiz.com\/vn\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#website\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"name\":\"Biz and Live in Saigon\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#organization\",\"name\":\"SaigonBiz Media\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png\",\"width\":512,\"height\":512,\"caption\":\"SaigonBiz Media\"},\"image\":{\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/SaigonbizGroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6\",\"name\":\"admin\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"contentUrl\":\"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png\",\"caption\":\"admin\"},\"sameAs\":[\"https:\/\/english.saigonbiz.com\/vn\"],\"url\":\"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - Biz and Live in Saigon","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/","og_locale":"en_US","og_type":"article","og_title":"Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting","og_description":"NORCROSS, Ga., Oct. 15, 2024 (GLOBE NEWSWIRE) &#8212; Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target ga","og_url":"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/","og_site_name":"Biz and Live in Saigon","article_publisher":"https:\/\/www.facebook.com\/SaigonbizGroup","article_published_time":"2024-10-15T12:05:27+00:00","og_image":[{"width":1,"height":1,"url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2024\/10\/Galectin-Therapeutics-Inc-.png","type":"image\/png"}],"author":"admin","twitter_card":"summary_large_image","twitter_misc":{"Written by":"admin","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/#article","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/"},"author":{"name":"admin","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6"},"headline":"Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting","datePublished":"2024-10-15T12:05:27+00:00","dateModified":"2024-10-15T12:05:27+00:00","mainEntityOfPage":{"@id":"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/"},"wordCount":469,"publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"articleSection":["Pr Newswire"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/","url":"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/","name":"Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting - Biz and Live in Saigon","isPartOf":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#website"},"datePublished":"2024-10-15T12:05:27+00:00","dateModified":"2024-10-15T12:05:27+00:00","breadcrumb":{"@id":"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/english.saigonbiz.com\/vn\/galectin-therapeutics-announces-acceptance-of-three-abstracts-for-the-american-association-for-the-study-of-liver-diseases-aasld-2024-liver-meeting\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/english.saigonbiz.com\/vn\/"},{"@type":"ListItem","position":2,"name":"Galectin Therapeutics Announces Acceptance of Three Abstracts for the American Association for the Study of Liver Diseases (AASLD) 2024 Liver Meeting"}]},{"@type":"WebSite","@id":"https:\/\/english.saigonbiz.com\/vn\/#website","url":"https:\/\/english.saigonbiz.com\/vn\/","name":"Biz and Live in Saigon","description":"","publisher":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/english.saigonbiz.com\/vn\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/english.saigonbiz.com\/vn\/#organization","name":"SaigonBiz Media","url":"https:\/\/english.saigonbiz.com\/vn\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/cropped-c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview.png","width":512,"height":512,"caption":"SaigonBiz Media"},"image":{"@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/SaigonbizGroup"]},{"@type":"Person","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/267b348e6cf32a66aab33637c2d399a6","name":"admin","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/english.saigonbiz.com\/vn\/#\/schema\/person\/image\/","url":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","contentUrl":"https:\/\/english.saigonbiz.com\/vn\/wp-content\/uploads\/2026\/03\/c2adea16-1c71-4315-8801-803a8d237e2a_removalai_preview-2_uwp_avatar_thumb.png","caption":"admin"},"sameAs":["https:\/\/english.saigonbiz.com\/vn"],"url":"https:\/\/english.saigonbiz.com\/vn\/profile\/admin\/"}]}},"_links":{"self":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60561","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/comments?post=60561"}],"version-history":[{"count":0,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/posts\/60561\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media\/60562"}],"wp:attachment":[{"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/media?parent=60561"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/categories?post=60561"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/english.saigonbiz.com\/vn\/wp-json\/wp\/v2\/tags?post=60561"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}